Biogen Inc. (BIIB)
NASDAQ
Healthcare
Drug Manufacturers - General
$191.95
▼ -8.17%
Market Cap
$28.34B
Sector
Healthcare
Industry
Drug Manufacturers - General
Beta
0.16
52-Wk Range
121.05-219.72
CEO
Christopher A. Viehbacher
Country
US
Currency
USD
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selec…
Open full interactive analysis & DCF →